News
Bakker estimates that hundreds of compounds left on big pharma’s shelves could become much-needed drugs, but she acknowledges ...
Live Updates Live Coverage Updates appear automatically as they are published. Investors Don't Like the Taste of Yum! 9:37 am ...
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
Pfizer's Albert Bourla told investors that major drugmakers are "ready to to roll up their sleeves" and build out more direct ...
Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...
Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.
Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...
As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...
Pfizer reported a jump in second-quarter profits Tuesday behind higher sales of Covid-19 products and some other pharmaceuticals, while also benefiting from lower expenses.
Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.
CEO says pharma executives discussed Trump's call to launch DTC initiatives under his Most Favored Nation policy to lower U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results